Skip to main content
Premium Trial:

Request an Annual Quote

Celsee, IncellDx to Commercialize Assays After Cancer Study Collaboration

NEW YORK (GenomeWeb) – Celsee said today that it has entered a co-commercialization agreement with IncellDx for several products, including a 20-marker lung cancer genomics and proteomics panel, a CTC-based screening test for breast, colorectal, prostate, and other cancers, and a cell-based NIPT assay.

The companies said that their announcement follows the successful completion of a feasibility study that analyzed PD-L1 expression in lung cancer biopsy and blood specimens using the IncellDx OncoTect iO Single Cell Quantitative PD-L1 assay and the Celsee C-Prep Genesis platform.

In the study, which was presented last year at the annual meeting of the Association for Molecular Pathology, several patient samples showed a positive expression for PD-L1 in CTCs using the companies' combined technologies, but showed only minimal expression using standard-of- care methods.

"The coupled ability of IncellDx's technology to generate single cell suspensions with Celsee's technology to isolate and analyze single cells derived from peripheral blood and tissue will create a new standard for clinical research and for future diagnostic applications," Celsee CEO John Stark said in a statement.

Financial terms of the agreement were not disclosed.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.